Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelography using iohexol (Omnipaque).

F Peeters

    Diagnostic Imaging in Clinical Medicine
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Iohexol, a non-ionic contrast agent, demonstrated a favorable safety profile in myelography. Most patients experienced no adverse reactions, with only minor neurological or EEG changes observed in a few cases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study.

    ESMO gastrointestinal oncology·2026
    Same author

    The unjustified fear of erdafitinib-induced central serous retinopathy.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study.

    Clinical colorectal cancer·2024
    Same author

    The DizzyQuest: relation between self-reported hearing loss, tinnitus and objective hearing thresholds in patients with Meniere's disease.

    Journal of neurology·2021
    Same author

    Oxic methanogenesis is only a minor source of lake-wide diffusive CH<sub>4</sub> emissions from lakes.

    Nature communications·2021
    Same author

    Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohort.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2020
    Same journal

    A case of a gigantic ameloblastoma.

    Diagnostic imaging in clinical medicine·1986
    Same journal

    Early detection of bone metastases of Ewing's sarcoma by magnetic resonance imaging.

    Diagnostic imaging in clinical medicine·1986
    Same journal

    Left partial absence of the pericardium.

    Diagnostic imaging in clinical medicine·1986
    Same journal

    Inventory of medical X-ray equipment in Dutch hospitals.

    Diagnostic imaging in clinical medicine·1986
    Same journal

    Genetically significant diagnostic X-ray dose in The Netherlands.

    Diagnostic imaging in clinical medicine·1986
    Same journal

    Peripheral veno-lymphatic communications.

    Diagnostic imaging in clinical medicine·1986
    See all related articles

    Area of Science:

    • Radiology
    • Neurology
    • Pharmacology

    Background:

    • Myelography is a diagnostic imaging procedure used to visualize the spinal canal.
    • Non-ionic contrast agents are preferred for myelography due to their lower osmolality and reduced adverse effects.
    • Iohexol is a widely used non-ionic, low-osmolar iodinated contrast medium.

    Purpose of the Study:

    • To evaluate the safety and tolerability of iohexol in patients undergoing myelography.
    • To assess the incidence of adverse reactions following iohexol administration for myelography.
    • To monitor neurological status and electroencephalogram (EEG) changes post-myelography.

    Main Methods:

    • Myelography was performed in 30 patients using iohexol (Omnipaque) at concentrations of 240 mg I/ml (C1-C2 injections) or 300 mg I/ml (lumbar injections).

    Related Experiment Videos

  • Doses ranged from 3 to 10 ml.
  • Patients were monitored for 48 hours for adverse reactions, with neurological examinations repeated at 24 hours and EEG recordings taken between 3-24 hours post-procedure.

    • Main Results:

    • Adverse reactions were reported in 4 out of 30 patients (13.3%).
    • Minor EEG changes were observed in 1 patient (3.3%).
    • Slight alterations in neurological status were noted in 2 patients (6.7%).

    Conclusions:

    • Iohexol appears to be a safe and well-tolerated contrast agent for myelography.
    • The incidence of adverse reactions and neurological changes associated with iohexol myelography is low.
    • Further studies may be warranted to confirm these findings in larger patient cohorts.